Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above 50-Day Moving Average - Should You Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) shares passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.79 and traded as high as $0.89. Karyopharm Therapeutics shares last traded at $0.85, with a volume of 144,083 shares trading hands.

Analysts Set New Price Targets

KPTI has been the subject of a number of recent research reports. Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Finally, StockNews.com raised Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Karyopharm Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $4.80.

Karyopharm Therapeutics Price Performance

The company's fifty day simple moving average is $0.79 and its 200 day simple moving average is $0.94. The stock has a market capitalization of $106.04 million, a price-to-earnings ratio of -0.67 and a beta of 0.20.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. As a group, analysts anticipate that Karyopharm Therapeutics Inc. will post -0.93 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock valued at $649,000 after acquiring an additional 622,194 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $494,000. Acadian Asset Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $167,000. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $31,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Karyopharm Therapeutics in the second quarter valued at about $143,000. Institutional investors own 66.44% of the company's stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).